RGS4 and Parkinson disease: To test this, we examined the effect of selectively ablating RGS4 from dMSNs in 6-OHDA–lesioned mice treated for 7 to 8 days with daily intraperitoneal injections of l-DOPA (2 mg/kg) plus benserazide (12 mg/kg) (Fig. 5B), a treatment paradigm that elicited both therapeutic antiparkinsonian effects (Fig. 5E) and AIMs typical of LID (Fig. 5F) in this PD mouse model.